University of Colorado School of Medicine

Cardiometabolic Health Congress Becomes First Organization to Offer Certification in Cardiometabolic Health

Retrieved on: 
Thursday, November 9, 2023
Knowledge, CCHP, Research, Practitioner, National Center for Health Statistics, CKM, University of Colorado School of Medicine, National Center for Research Resources, Health, Obesity, Physician, Congress, American Heart Association, MD, Certification, Diabetes, Type 2 diabetes, University of Colorado Hospital, Medicine, Hypertension, Annual, Systemic, Kidney disease, University, CMHC, AHA, Pharmacist, Nursing, Dyslipidemia, Atherosclerosis, Pharmaceutical industry

Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now have the opportunity to sit for the Certified Cardiometabolic Health Professional (CCHP) examination.

Key Points: 
  • Boca Raton, FL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cardiometabolic Health Congress (CMHC) announced today that learners who complete its Foundations of Cardiometabolic Health Certificate Course now have the opportunity to sit for the Certified Cardiometabolic Health Professional (CCHP) examination.
  • Regarding the certification announcement, Dr. Eckel said, "I cannot overstate the tremendous implications of having a dedicated certification on the entire field of cardiometabolic health.
  • The Foundations of Cardiometabolic Health Certificate Course is currently open for enrollment to physicians, nurses, residents, fellows, and any other health professional interested in furthering their knowledge in the core principles of cardiometabolic health.
  • Cardiometabolic Health Congress (CMHC) is a single point of access for breakthrough research, comprehensive education, and practical clinical strategies surrounding cardiometabolic health.

New SeriousFun Children's Network Study Discovers Improved Sense of Purpose in Medical Volunteers

Retrieved on: 
Thursday, November 9, 2023
Children's Hospital Colorado, Rejuvenation, National Association Medical Staff Services, Caregiver, Volunteering, Frustration, University of Colorado School of Medicine, Medicine, SeriousFun Children's Network, Patient, University, Nursing, Tourism, Network

NORWALK, Conn., Nov. 9, 2023 /PRNewswire/ -- SeriousFun Children's Network (SeriousFun), the leading network of medical specialty camps in the world, has released a new report offering unique insight into the potential of medical specialty camps to positively affect the well-being of medical professionals caring for children.

Key Points: 
  • Volunteers reported positive camp experiences with 99% feeling included and a sense of purpose.
  • Importantly, medical volunteers experienced their pediatric patients in a new light which increased appreciation of their positive impact on patients' lives.
  • "SeriousFun recognizes the importance of offering medical providers opportunities to build stress resilience and coping skills that translate to their day-to-day work," said Dr. Laura Blaisdell, Medical Advisor, SeriousFun Children's Network.
  • SeriousFun Children's Network is continuously working to grow its reach and impact by creating positive, inclusive, and empowering experiences for campers, families, caregivers, volunteers, medical professionals, and communities.

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform

Retrieved on: 
Thursday, November 2, 2023
Acute myeloid leukemia, Doctor of Philosophy, Cell, HIV disease progression rates, Division, Abstract (summary), Abstract, Head, HCT, Exposition, Hospital, CAR, Janssen, Bone marrow, CHOP, Haematopoiesis, University, Toxicity, Safety, Therapy, Transplant, MSCE, Pediatric Transplantation, Lymphoma, ASH, Clinical trial, Prognosis, Cytokine release syndrome, Biomarker, CRS, Investigator's brochure, The Relapse, University of Colorado School of Medicine, CRISPR, Phenotype, Society, National Cancer Institute, CD33, Associate, AML, Nursing, Rare-earth element, Dentistry, Vaccine, Mobile phone, Pharmaceutical industry, Child, Pediatrics, Diagnosis, Patient, MD, Leukemia

An abstract providing a clinical update from the VBP101 clinical trial (NCT048499910), a Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with AML, was accepted by ASH for oral presentation.

Key Points: 
  • An abstract providing a clinical update from the VBP101 clinical trial (NCT048499910), a Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with AML, was accepted by ASH for oral presentation.
  • This data supports robust neutrophil engraftment of trem-cel and provides evidence of hematologic protection from MylotargTM, a CD33-targeted antibody drug conjugate.
  • An updated data release from VBP101 is expected by the Relapse After Transplant and Cellular Therapy (HSCT²) conference taking place November 10-11, 2023.
  • Dr. Tasian commented: “The interim results from our CD33 CAR T cell immunotherapy clinical trial are very encouraging.

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

Retrieved on: 
Thursday, November 2, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Knowledge, Dell Medical School, University of Washington School of Medicine, SMMT, University of Colorado School of Medicine, Associate, Therapy, University, Lung cancer, Head, MD, University of Texas at Austin, Drug, University of Ottawa Heart Institute, Thyroid, Summit, Drug development, Senior, Quality of life, Lung, Disease, JAMA Otolaryngology–Head & Neck Surgery, Immunotherapy, Patient, Moses Austin, Pharmaceutical industry

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.
  • We are very excited to welcome Laura to our team.”
    Dr. Chow remains in active clinical practice as a medical oncologist specialized in lung and head and neck cancers.
  • She joins Summit from Fate Therapeutics, where she was the Vice President of Clinical Development in Solid Tumors.
  • Chow’s experience being on the ground floor of cancer immunotherapy is unmatched,” added Dr. Allen S. Yang, Chief Medical Officer at Summit.

The Inner Circle Acknowledges, Timothy Kruse as a Most Trusted Business Professional for his contributions to the field of Accounting

Retrieved on: 
Friday, November 3, 2023
Patient, Stroke, Medical school, University of Colorado School of Medicine, Health, Health care, AAFP, Family therapy, MD, Carleton College, Master, AMA, Medical degree, House, Inner circle, School, American Academy, University, Woman, American Academy of Family Physicians, Memory, Nursing, Family medicine, Biology, Medicine, Marriage

BASALT, Colo., Nov. 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Timothy Kruse is acknowledged as a Healthcare Professional for his contributions to the field of Family Medicine.

Key Points: 
  • BASALT, Colo., Nov. 3, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Timothy Kruse is acknowledged as a Healthcare Professional for his contributions to the field of Family Medicine.
  • He completed a Medical Degree from the University of Colorado, School of Medicine in 1996; completed a residency in family medicine at St. Joseph Family Practice Hospital in Denver.
  • Dr. Kruse is a trusted family physician with Premier Medical Center pioneering a new personalized approach to medical care in Basalt Colorado.
  • Dr. Kruse would like to dedicate this honor in memory of his mentor, Dr. Thomas, MD and thank his father, Mr. Richard Kruse, for all his support.

VALUABLE NEW DATASET GIVES INSIGHT INTO LINKS AMONG PEDIATRIC CONDITIONS

Retrieved on: 
Thursday, November 2, 2023
DS, Acute lymphoblastic leukemia, National Institutes of Health, University of Colorado School of Medicine, Syndrome, National Institutes of Health Common Fund, Ventricular septal defect, TB, Data, Birth, Kid, Nickelodeon (Australia and New Zealand), Research, Baylor College of Medicine, Investigation, INCLUDE, Down syndrome, Biology, Partnership, Emory University, Leukemia, B-ALL, University, NIH, Cancer, Collection, Patient, HTP, Data hub, Bangladesh Technical Education Board, Pharmaceutical industry, Publishing, Lifespan

This data has revealed unique B-ALL genetic features in those with DS, which can lead to improving therapies for all.

Key Points: 
  • This data has revealed unique B-ALL genetic features in those with DS, which can lead to improving therapies for all.
  • At the same time, the INCLUDE Data Hub provides data on DS across the lifespan.
  • This collaboration has created a powerful opportunity for research analysis to identify the underlying causes of these different conditions.
  • Now, this data is available at no charge for general research use on the Kids First Data Resource Portal and the INCLUDE Data Hub.

Dynami Funds New Groundbreaking Research for Lobular Breast Cancer

Retrieved on: 
Wednesday, November 1, 2023
Dean (education), Karmanos Cancer Institute, Biomarker, Leigh, Doctor of Philosophy, Disease, Risk, Partnership, DRS, University of Michigan, UPMC, Fertility preservation, Hope, Physician, Hereditary lobular breast cancer, Impact, University of Pittsburgh Medical Center, IVF, Breast cancer, University, Morávek, Cancer, Patient, Biomedical engineering, ILC, University of Colorado, History, MD, Work, Woman, University of Colorado School of Medicine, Black, Multimedia, Recurrence, Personalized medicine, United States and Canadian Academy of Pathology, Medical device, Vaccine, Medical imaging, Birth control, Pharmaceutical industry, Research, Pathology, Pharmacology, Dynamy

DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health. Recently released University of Michigan Health Impact Report outlines the progress and work made possible by the Dynami Foundation's initiatives that are focused on transforming the future of invasive lobular breast cancer (ILC) through the funding of research.

Key Points: 
  • DETROIT, Nov. 1, 2023 /PRNewswire/ -- The Dynami Foundation has funded groundbreaking new research and support for lobular breast cancer through their partnership with University of Michigan Health.
  • From groundbreaking new research on circulating cells to a dual-institution effort to combat cancer, Dynami and University of Michigan have partnered to drive progress.
  • A patient-centered decision-making process by understanding goals of lobular breast cancer patients for an elevated, personalized breast reconstruction experience led by Dr. Paige Myers.
  • Dynami has funded over 12 research projects and will continue to fight for advancement for lobular breast cancer just like the incredible work and impact that we've made here."

Mironid appoints Dr Catherine Kelleher as Chief Medical Officer

Retrieved on: 
Tuesday, October 24, 2023
University of Colorado School of Medicine, Cass, Therapy, Rare, ADPKD, Nephrology, Drug, Drug development, Senior, Amgen, University, Patient, Autosomal dominant polycystic kidney disease, Associate, Rheumatology, Pharmaceutical industry, Medicine

October 24 2023, Glasgow, Scotland – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a serious hereditary kidney disease, today announces the appointment of Dr Catherine (Cass) Kelleher as Chief Medical Officer.

Key Points: 
  • October 24 2023, Glasgow, Scotland – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a serious hereditary kidney disease, today announces the appointment of Dr Catherine (Cass) Kelleher as Chief Medical Officer.
  • Cass most recently served as Chief Medical Officer at Anteris Bio and previously as Senior Vice President of Clinical Development at ChemoCentryx.
  • “Mironid has the potential to improve the ADPKD disease space by offering a first-in-class, innovative molecule to treat patients with ADPKD and possibly other rare diseases,” commented Dr Cass Kelleher, Chief Medical Officer of Mironid.
  • “I look forward to helping make this a reality, working closely with the executive team at Mironid as we work to progress our treatment into the clinic.”
    “I am delighted to welcome Cass as Chief Medical Officer to the team here at Mironid,” commented Dr Neil Wilkie, Chief Executive Officer of Mironid.

ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes

Retrieved on: 
Saturday, October 21, 2023
Science, Other Science, Biotechnology, Research, Oncology, General Health, Health, Other Health, Patient, University of Colorado School of Medicine, Pneumonitis, Hypophysitis, ESMO, Biomarker, Clinical research, Congress, European Society for Medical Oncology, BAL, MD, BOT, Inc., Cancer, Sarcoma, Immunotherapy, University, Anschutz Medical Campus, Leiomyosarcoma, Hepatitis, Safety, Myocarditis, Pharmaceutical industry, Medical imaging

The results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • The results were presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023.
  • Relapsed/refractory sarcoma represents a significant unmet medical need where existing standard of care options and previous immunotherapies have shown limited activity.
  • The sarcoma cohort presented is part of a larger phase 1b study evaluating the safety, efficacy, and dose optimization of BOT alone and in combination with BAL in multiple advanced solid tumors.
  • "Notably, we observed several durable responses extending past one year, including patients with visceral angiosarcoma, which is traditionally unresponsive to immunotherapy, as well as other cold subtypes like leiomyosarcoma.

Dr. Karin B. Cesario Joins Peak Gastroenterology Associates

Retrieved on: 
Friday, October 13, 2023
Managed Care, General Health, Health, Other Health, University of Colorado School of Medicine, Peak, Cleveland Clinic, University, OH, Cleveland, GCP, Fellow, American Gastroenterological Association, Patient, Gastroenterology, Hospital

Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado, today announced Karin B. Cesario, M.D.

Key Points: 
  • Peak Gastroenterology Associates (“Peak” or “the Company”), the largest provider of gastroenterology and related ancillary diagnostic and therapeutic services in Colorado, today announced Karin B. Cesario, M.D.
  • “We are absolutely thrilled to have Dr. Cesario join the Peak team,” said Dr. Prashant Krishnan, a Peak care provider and Gastro Care Partners’ Chief Medical Officer.
  • Peak is the fastest growing and largest gastroenterology practice in Southern Colorado.
  • Peak is a preferred partner of Gastro Care Partners.